Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.

ABSTRACT:

Objective

To compare real-world effectiveness and safety of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (AFib) for prevention of stroke.

Study design and setting

A comparative cohort study in UK general practice data from The Health Improvement Network database.

Participants and interventions

Before matching, 5655 patients ≥18 years with nonvalvular AFib who initiated at least one DOAC between 1 July 2014 and 31 December 2020 were included. DOACs of interest included apixaban, rivaroxaban, edoxaban and dabigatran, with the primary comparison between apixaban and rivaroxaban. Initiators of DOACs were defined as new users with no record of prescription for any DOAC during 12 months before index date.

Primary and secondary outco

SUBMITTER: Jaksa A 

PROVIDER: S-EPMC9577930 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature